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With the exception of nucleoside analogs, few direct acting antivirals in clinical development are active
across the six major hepatitis C virus genotypes. We report novel consensus sequence chimeras for
genotypes 2b, 3a, 4a, 5a, and 6a NS5B and show variable susceptibilities over a panel of NS5B inhibitors.
Tegobuvir (GS-9190) had EC50s of o16 nM against genotype 1 and 4100 nM for other genotypes
tested here. An NS5B F445C mutation engineered into the GT3a, 4a, and 6a chimeric replicons lowered
the tegobuvir EC50 to levels comparable to those for genotype 1a, but did not considerably alter the EC50
of site 2 or nucleoside analog inhibitors. These data support the use of HCV chimeras in proﬁling direct
acting antivirals across genotypes and speciﬁcally determines the impact of the C445F NS5B
polymorphism on tegobuvir potency against genotypes 3a, 4a, and 6a.
& 2012 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV) infection is a global health concern
with approximately 170 million individuals infected worldwide
(Anon, 1999). There are at least 6 main genotypes and multiple
subtypes of HCV with the most common being genotype 1a in
North America and Europe (Bukh et al., 1993; Simmonds et al.,
2005). It is estimated that genotypes 4, 5, and 6 account for 420%
of infections worldwide (Antaki et al., 2010). HCV infection may
lead to serious liver diseases including liver ﬁbrosis and cirrhosis,
hepatic failure, and hepatocellular carcinoma. It is also the most
common indication for liver transplantation; approximately 40–
50% of patients on the liver transplant waiting list are infected
with HCV (Brown, 2005). The standard of care has been pegylated
interferon-a and ribavirin (PegþRIBA) for 48 weeks. While this
treatment leads to 80–90% sustained virologic response (SVR) in
genotype 2 or 3 patients, there is only a 40–50% SVR rate in
patients infected with HCV genotype 1 (Fried et al., 2002; Manns
et al., 2001). The recent approval of two new HCV NS3 protease
inhibitors, telaprevir and boceprevir, in combination with
PegþRIBA will increase SVR rates and shorten treatment dura-
tions, however they are only approved for genotype 1 HCV
infection (Hofmann and Zeuzem, 2011; Jacobson et al., 2011;
Poordad et al., 2011).ll rights reserved.
g).Investigational agents targeting other HCV proteins such as the
RNA dependent RNA polymerase NS5B have shown potent anti-
viral activity both in vitro and in vivo. NS5B inhibitors are
typically divided into two classes: nucleoside analogs and non-
nucleoside inhibitors (NNIs). Nucleoside analogs target the active
site of NS5B and serve as chain terminators to prevent elongation
and replication of the HCV RNA genome. NNIs are a more
structurally diverse set of NS5B inhibitors targeting multiple sites
on the NS5B polymerase. Nucleoside analogs generally have
activity across multiple HCV genotypes as incorporation of a
chain terminating base is indiscriminate of the polymerase
genotype. In contrast, the available NNIs target at least 4 different
allosteric sites on the NS5B polymerase (Legrand-Abravanel et al.,
2010). Site 1 and site 2 sit in the thumb domain of the
polymerase. Site 2 inhibitors in phase 2 development include
VX-222 (thiophene carboxylic acid) and ﬁlubivir (dihydroxypir-
one). Site 3 sits in the palm domain of the polymerase and is
targeted by the Abbott compounds ABT333 and A-837093. Site
4 also sits in the palm domain and is targeted by the benzofuran
HCV-796. Tegobuvir (GS-9190) is different in that it is considered
a site 3/4 inhibitor. Since the NNIs target diverse sites on the
polymerase there is sufﬁcient amino acid variability in these
regions to impact the potency of these compounds when com-
pared across genotypes (Herlihy et al., 2008).
Determining the antiviral potency of direct acting antiviral
compounds targeted against the NS3 protease, NS5A, and the
NS5B polymerase in HCV genotypes 3–6 has been hampered by
the lack of complete and robust sub-genomic replicons or viral
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Fig. 1. Structures of NS5B inhibitors.
K.A. Wong et al. / Virology 429 (2012) 57–6258culture systems for these genotypes. Recently, several studies have
been published establishing the use of chimeric replicons and
viruses for speciﬁcally examining non-genotype 1 NS3, NS5A, and
NS5B. Several factors likely contribute to the replication success or
failure of these chimeras including the genotype of the vector
backbone used and its compatibility or similarity with the chimeric
genotype, the speciﬁc HCV gene to be studied, the site of genetic
cross-over in the gene, and the representative sequence used for
that gene. For the NS3 protease, chimeric replicons created on a
1b-con-1 backbone with the entire NS3/4A gene or NS3 protease
alone from genotypes 2b, 3a, and 4 showed variable replication
success (Binder et al., 2011). In an infectious 2a(J6/JFH-1) based
NS3/4A chimera system, only chimeras for genotypes 2a(J6), 3a, 5a,
and 6a showed viral spread in transfected Huh7.5 cells (Gottwein
et al., 2011). For NS5A, recombinant viruses were successfully
established on the 2a (J6/JFH1) virus system with full length NS5A
from genotypes 1–7 (Scheel et al., 2011). For the HCV NS5B
polymerase, chimeric replicons were successfully established on
a 1b-con-1 backbone using NS5B sequences derived from patients
for genotypes 2b, 3a, 4a, and 5a (Herlihy et al., 2008). In all of these
studies, HCV inhibitors displayed variable activity against chimeras
dependent on the genotypes of the target genes and highlighted
the utility of chimeric replicons and viruses.
Tegobuvir, a NS5B non-nucleoside polymerase inhibitor, has
demonstrated potent activity against genotypes 1a and 1b HCV in
vitro in HCV replicons, and in vivo in HCV genotype 1-infected
patients (Lawitz et al., 2011; Shih et al., 2011). Our current study
aims to determine the antiviral activity of tegobuvir against HCV
genotypes 2b, 3a, 4a, 5a, and 6a. A series of chimeric HCV replicons
were constructed using both published sequences for these
genotypes (Herlihy et al., 2008) as well as consensus sequences
generated from NS5B sequences available in the EU and Los
Alamos HCV databases. In addition to tegobuvir, we also examined
NNIs targeting the site 2 thumb domain and the site 3 and 4 palm
domain of NS5B. Furthermore, in genotype 1b, the C445F mutation
is reported to cause a 7.1 fold increase in EC50 (Shih et al., 2011).
This amino acid position is polymorphic between genotype 1 and
genotypes 2–6. In genotypes 1a and 1b, the NS5B 445 amino acid
is cysteine, while in genotypes 2–6, the residue is phenylalanine.
To further characterize this polymorphism’s role in tegobuvir
potency versus different genotypes, the NS5B phenylalanine at
position 445 in our genotype 2b, 3a, 4a, 5a, and 6a chimeras weremutated to match the genotype 1 cysteine residue (F445C) and
assessed for tegobuvir susceptibility.Results
Construction and replication capacity of NS5B genotype chimeras
A HCV 1b-con-1 subgenomic replicon was used as the base for
construction of NS5B chimeras. This replicon also contains the
Renilla luciferase gene and is designated as 1b-hRLuc. The last 413
base pairs (encoding the last 137 NS5A amino acids) of 1b-con-1
NS5A were synthesized in frame with NS5B from reported
sequences for NS5B derived from patient isolates (Herlihy et al.,
2008) with HCV genotype (GT) 2b, 3a, 4a, 5a, and 6a infections.
The 30-UTR from 1b-con-1 remained intact and the resultant
chimeras were identical to the 1b-con-1 sequence except for the
region encoding NS5B (Fig. 2). This series of chimeras is designated
as ‘‘clinical isolates’’ (CI) hereafter. In addition to using the NS5B
sequences found in Herlihy et al. (2008), a consensus sequence
was derived by multiple alignment using NS5B sequences avail-
able in the EU Database for HCV genotypes 2b, 3a, 4a, 5a, and 6a
(Supplemental Table 1). Multiple alignment of the primary amino
acid sequence among these new consensus sequences with those
for 1a-H77, 1b-con-1, and 2a-JFH1 showed greater than 74%
identity across genotypes (Table 1). The NS5B consensus for each
of these genotypes was also synthesized in frame with the 413 bp
of 1b-con-1 NS5A and the entire cassette was cloned into the
1b-hRLuc/NeoR NS5B shuttle vector as described above. This series
of chimeras is designated as ‘‘consensus’’ (Con) hereafter.
To test the replication capacity of these chimeras, replicon RNA
was transiently transfected into Huh7-lunet cells and luciferase
activity was measured at 4 and 72 h post transfection. These
results are summarized in Fig. 3. For GT2b CI and Con chimeras,
replication capacity was similar with luciferase readings near
1000. Both GT4a chimeras also replicated well with the GT4a
Con chimera replicating to a higher level than the GT4a CI
chimera. In contrast, the GT3a and GT6a Con chimeras replicated
well while the GT3a and GT6a CI chimeras did not replicate above
background luciferase levels; this is consistent with results
reported by Herlihy et al. for these CI chimeras. The opposite
was observed for GT5a chimeras; the CI chimera replicated well,
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Fig. 2. Cloning of NS5B chimeric replicons. A genotype 1b HCV subgenomic NS3-NS5B replicon with bi-cistronic expression of the Renilla luciferase and neomycin
resistance genes was used as the backbone for construction of NS5B chimeras. This replicon contains an internal deletion in NS5B rendering it replication deﬁcient (D5B).
GT1b NS5A was synthesized from the indicated unique XhoI site to the junction with NS5B; at which point the DNA sequence for C.I. or Con NS5B from GTs 2b, 3a, 4a, 5a,
and 6a was synthesized through the stop codon and unique AseI site. XhoI-AseI cassettes containing the in-frame GT1b-(NS5A) to GTx-(NS5B) were cloned into the base
replicon via the unique XhoI and AseI sites.
Table 1
NS5B amino acid identity across HCV genotypes. The primary amino acid sequence
for NS5B from HCV 1a-H77, 1b-con-1, 2a-JFH1, 2b-Con, 3a-Con, 4a-Con, 5a-Con,
and 6a-Con were aligned by AlignX (Vector NTi). Amino acid identities were
compared across genotypes and the percent of identical residues were calculated
pairwise.
1a H77 1b Con 2a JFH1 2b Con 3a Con 4a Con 5a Con 6a Con
1a H77 88 74 76 75 78 76 80
1b Con 75 75 76 78 78 80
2a JFH1 88 76 76 76 76
2b Con 76 77 77 77
3a Con 83 77 80
4a Con 77 80
5a Con 77
6a Con
1b 2b 3a 4a 5a 6a
1
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Fig. 3. Replication capacity of NS5B chimeras. Replication capacity was measured
for both the clinical isolate (CI) and consensus (Con) NS5B chimeras by transient
transfection into Huh7-lunet cells followed by measurement of Renilla luciferase
activity 72 h post transfection. The log10 relative luciferase units were plotted for
all the replicons tested. 1b-con-1 was used as a positive control. Light shaded bars
are luciferase activity from CI chimeras and dark shaded bars are from Con
chimeras. Dashed line represents background luciferase reading for no transfec-
tion control.
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genotype 3a, 5a, and 6a chimeras, the NS5B amino acid differences
between the CI and Con chimeras were 9, 20, and 19 residues,
respectively (Supplemental Table 2). For all of the Con NS5B
chimeras except GT5a, stable cell lines were generated by serial
passaging of transfected cells with G418 in cell culture. A cell line
was also established by G418 selection for the GT5a CI chimera.
NS5B chimera susceptibility to HCV polymerase inhibitors
To determine the susceptibility of the NS5B chimeras to
tegobuvir (GS-9190) and other NS5B inhibitors acting on diverse
sites in the polymerase, stable cell lines harboring chimeric
replicons were treated with either, tegobuvir, the benzimidazole
site 1 NNI JT-16, a thiophene carboxylic acid site 2 NNI, the
benzofuran site 4 NNI HCV-796, the benzothiadiazine site 3 NNI
A-837093, or the nucleoside inhibitor 20-C-Methyl-Adenosine
(Fig. 1). Table 2 shows the EC50 (nM) for all compounds tested
against the 1b-con-1 replicon and the fold shift in EC50 for the
other compounds compared to 1b-con-1. Consistent with pre-
vious data, tegobuvir is the most potent versus the 1b-con-1
replicon with an approximately 10 fold lower shift in EC50 against
the 1a-H77 replicon (Shih et al., 2011). Treatment of 2a-JFH1
replicon and GT3a, 4a, 6a-Con, and 5a CI chimeras produced fold
shifts varying from 57 to 14,700 less susceptibility to tegobuvir.
For other NNIs tested, the benzimidazole site 1 NNI JT-16 had
fold shifts in EC50 compared to 1b-con-1 ranging from none (1.0)
for GT5a to 144 fold for GT2b. The thiophene carboxylic acid
site 2 inhibitor had fold shifts in susceptibility ranging from alow 9.0 fold versus the GT5a CI and a high of 3160 fold shift
versus the 2a-JFH1 replicon. The benzothiadiazine A-837093
NS5B site 3 inhibitor only showed single digit nanomolar EC50s
against GT1b and GT1a replicons. Fold shifts for this compound
ranged from a low of 105 fold against GT4a Con to a high of 3398
fold against the 2a-JFH1 replicon. In contrast to the other NNIs,
the benzofuran HCV-796 NS5B site 4 inhibitor had the least
amount of EC50 variability across the genotypes tested, with the
highest fold shift being 18.4 fold versus the 2a-JFH1 replicon. The
EC50 of HCV-796 was decreased by nearly 10 fold against GT5a CI
when compared to 1b-con-1.
The active site nucleoside inhibitor 20-C-Methyl-Adenosine
was also tested across the NS5B genotypes. This nucleoside
analog showed similar potency across genotypes tested with the
highest EC50 fold shift of 2.1 versus the 2a-JFH1 replicon. As a
control, an HCV NS3 protease inhibitor was assayed and showed
minimal fold shifts across the NS5B chimeras consistent with the
chimeras all containing the 1b-con-1 NS3 protease (Table 2).
Tegobuvir potency is reduced in GT3a, 4a, and 6a by the F445
polymorphism
Resistance selection with tegobuvir in 1b-con-1 replicon
identiﬁed several mutations contributing resistance, including
C316Y, C445F, Y448H, and Y452H (Shih et al., 2011). Furthermore,
Table 2
Comparison of anti-viral activity of tegobuvir and other known HCV NS5B inhibitors against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a. EC50 values in nM were
determined for 1a-H77, 1b-con-1, and 2a-JFH1 full replicons and 2b-Con, 3a-Con, 4a-Con, 5a-CI, and 6a-Con stable chimeric replicon cell lines. Fold changes in EC50 were
calculated against the 1b-con-1 EC50 value. Results represent the average of at least 2 independent experiments.
Protease inhibitor Tegobuvir (GS-9190) Thiophene carboxylic acid A-837093 HCV-796 JT-16 20C-Methyl-A
EC50 FC/1b EC50 FC/1b EC50 FC/1b EC50 FC/1b EC50 FC/1b EC50 FC/1b EC50 FC/1b
Full replicon
1b 32.7 1.0 1.5 1.0 4.4 1.0 3.7 1.0 8.5 1.0 109.3 1.0 371.7 1.0
1a 84.5 2.6 15.9 10.6 14.5 3.3 6.8 1.8 7.7 0.9 1624 14.9 303.1 0.8
2a 271.9 8.3 22,050 14,700 13,904 3160 12,574 3398 156.4 18.4 7408 67.8 798.7 2.1
NS5B chimeras
2b 77.8 2.4 6710 4473 8862 2014 2928 791 16.2 1.9 15,742 144.0 293.5 0.8
3a 20.2 0.6 1382 921 4466 1015 3879 1048 29.8 3.5 610.3 5.6 299.3 0.8
4a 36.2 1.1 992 661 2908 661 388.2 105 16.2 1.9 1826 16.7 209.6 0.6
5a 24.3 0.7 104 69 39.6 9.0 746.9 202 1.1 0.1 108.1 1.0 130.9 0.4
6a 20.5 0.6 85.5 57 2961 673 1388 375 16.2 1.9 1343 12.3 251.6 0.7
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Fig. 4. The NS5B F445C mutation restores tegobuvir potency against HCV GT3a, 4a, and 6a. EC50 (nM) is plotted for tegobuvir, 20-C-Methyl-Adenosine, and the thiophene
carboxylic acid for GT1a and 1b replicons and 3a, 3a F445C, 4a, 4a F445C, and 6a, 6a F445C chimeric replicons. EC50 values are calculated from at least 2 independent
experiments.
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treated with tegobuvir (Hebner et al., 2011; Mo et al., 2011).
Mutation at NS5B position C316 is a site of cross resistance for
tegobuvir and HCV-796. HCV-796 has been reported to have a 166
fold shift in EC50 to the C316Y mutation and a 26 fold shift to
C316N mutation (Howe et al., 2008). For comparison, the fold shift
in EC50 for the C316Y and C316N mutations against tegobuvir are
9 (Shih et al., 2011) and 5 fold (Mo et al., 2011) respectively.
Multiple alignments of the NS5B amino acid sequences across
genotypes allowed us to determine if any of these resistance
mutations were present as amino acid polymorphisms in other
genotypes. For genotypes examined here, NS5B amino acids C316,
Y448, and Y452 remained unchanged compared to 1b-con-1. In
contrast, C445F was present in genotypes 2a, 2b, 3a, 4a, 5a, and 6a.
To determine if the C445F polymorphism contributes to the
reduced potency of tegobuvir in genotypes 2–6, the residues were
changed by site directed mutagenesis to cysteine (F445C) in the
chimeric replicons to match that of HCV genotype 1. The F445C
mutants were transfected into Huh7-lunet cells and luciferase
was read at 4 h and 72 h post transfection. The 2b and 5a F445C
mutants did not replicate, however, the 3a F445C mutant repli-
cated with an average relative luciferase unit reading of 17,449
at 72 h post transfection. The 4a and 6a F445C mutants had
luciferase readings between 400–1000 at 72 h post transfection
(data not shown). Selection of stable cell lines with G418 was
successful for F445C cell lines of genotypes 3a, 4a, and 6a Con.
Tegobuvir, 20C-Me-A, and the thiophene carboxylic acid suscept-
ibility was tested against these three F445C cell lines and compared
to the GT1a-H77 and 1b-con-1 replicons, and the HCV genotype 3a,4a, and 6a Con chimeras (Fig. 4). Tegobuvir was potent in GT1a and
1b with mean EC50s of 19.8 and 1.5 nM respectively. For genotype
3a, 4a, and 6a Con chimeras, tegobuvir EC50s were all greater than
100 nM. The F445C NS5B mutations in GT3a, 4a, and 6a chimeric
replicons restored tegobuvir potency to EC50 levels comparable to
GT1a. These increases in susceptibility for the F445C mutations
were not seen with the nucleoside inhibitor 20-C-Me-A or the
thiophene carboxylic acid NS5B site 2 inhibitor (Fig. 4).Discussion
This study utilized NS5B chimeric replicons to assess the
potency of the NS5B inhibitor tegobuvir in HCV genotypes 2b,
3a, 4a, 5a, and 6a. Several studies have used chimeric HCV
replicons or viruses to characterize drug susceptibility of HCV
genotypes for which full length replicons or viruses were not
available; however, to our knowledge, this is the ﬁrst study that
has successfully used a NS5B GT6a chimeric replicon. In compar-
ison to the non-replicating GT6a CI chimera, the consensus
sequence-derived GT6a Con chimera differs at only 19 amino
acid positions across the NS5B coding region. Transient replica-
tion assays show that the GT3a Con chimera had a 75 fold
increase in replication capacity compared to the GT3a CI chimera.
The difference in amino acid identity was only 9 residues in NS5B
when comparing the GT3a chimeras. Any one or combination
of these differing residues may be responsible for the ability of
the GT3a and GT6a Con chimeras to replicate better than their
respective CI chimeras. Conversely, the GT5a Con chimera did not
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ences between NS5B in these two chimeras is 20 amino acids;
similarly any one or combination of differences may be respon-
sible for the lack of replication of the GT5a Con chimera
(Supplemental Table 2). In this study, we have taken the approach
of using a 1b-con-1 replicon backbone and cloned in NS5B
from diverse genotypes. In a study by Muryama et al., genotype
2aJFH-1 and 2aJ6 replicons were used to create a series of chimeras.
A 2aJFH-1 backbone chimera with a 2aJ6 NS5Bþ30UTR was replica-
tion deﬁcient whereas the same chimera with only the coding
sequence for NS5B 2aJ6 replicated but had a more than 100-fold
reduction in replication capacity (Murayama et al., 2007). Due to the
loss of replication capacity, even when exchanging NS5B
for another sequence in the same 2a genotype, we chose not to
pursue the generation of NS5B chimeras using 2aJFH-1 as the
replicon backbone.
One restriction of the current study is the limited analysis of
subtypes within a given HCV genotype. There are clearly differ-
ences in susceptibility to direct acting antivirals among subtypes
as evidenced by the different fold shifts in EC50 observed in our
study between genotypes 1b and 1a and between genotypes 2a
and 2b. Nevertheless, in the absence of full replicons for less
common subtypes, a chimeric replicon approach could be succes-
fully employed to analyze additional HCV NS5B subtypes.
Overall, fold shifts in antiviral potency versus 1b-con-1 of a site
1 benzimidazole (JT-16), a site 2 thiophene carboxylic acid, site
3 benzothiadiazine (A-837093), a site 4 benzofuran (HCV-796),
and a nucleoside inhibitor (20-C-Me-A) were comparable to those
reported previously in HCV genotypes 1–5 (Herlihy et al., 2008).
Against the GT6a Con chimera, we measured an 11.6 fold shift in
EC50 over GT1b for the site 1 inhibitor JT-16, a 673 fold shift for the
thiophene carboxylic acid site 2 inhibitor, and a 3470 fold shift
with the site 3 inhibitor A-837093. Consistent with the broader
genotypic activity of active site nucleoside inhibitors and HCV-796,
the GT6a Con chimera was susceptible to both of these classes of
inhibitors within a 2-fold change from the 1b-con-1 susceptibility
(Table 2).
Tegobuvir is currently being studied in combination with other
direct acting antivirals for treatment of chronic genotype 1 HCV
infection in several Phase 2 clinical studies. We determined the
EC50 of tegobuvir against GT2b, 3a, 4a, 5a, and 6a NS5B chimeras
to evaluate its potency in non-genotype 1 replicon systems.
Tegobuvir potency against non-genotype 1 replicons generally
fell into two categories, highly resistant or moderately resistant.
The ﬁrst group consisted of genotypes 2a, 2b, 3a, and 4a with fold
shift increases in EC50 ranging from 661 to 14,700. The moder-
ately resistant genotype 5a and 6a replicons had tegobuvir EC50
fold shifts of 69 and 57 respectively (Table 2). It is interesting
to note that the lowest tegobuvir fold shift was observed with
GT6a Con, where the NS5B sequence is 80% identical to 1a-H77 and
1b-con-1 (Table 1). This is the highest amino acid identity between
GT1 and the non-GT1 NS5B sequences used in this study. However,
this trend was not consistent with the other NNIs tested here
suggesting that speciﬁc polymorphic residues or combinations of
residues impact NNI potency rather than the overall percent
identity to GT1.
In GT2–6 NS5B chimeras, the fold shift in EC50 was high for
tegobuvir. Non-genotype 1 HCV all possess phenylalanine at NS5B
position 445 in contrast to the cysteine in GT1a and 1b at the same
position. Mutation of F445 to C445 in the chimeras resulted in
replication competent subgenomic replicons for only GT3a, 4a, and
6a. This single amino acid change in these chimeras signiﬁcantly
reduced the EC50 for tegobuvir 410 fold when compared to their
wild-type chimeras. Although this potency increase did not bring
the tegobuvir susceptibility down to the level of 1b-con-1, it was
comparable to the EC50 for 1a-H77 replicon (16 nM). These dataindicate that a major factor in the lack of tegobuvir susceptibility in
GT3a, 4a, and 6a replicons can be attributed to their NS5B F445
polymorphism when compared to GT1. A query of the EU HCV
sequence database for GT3a, 4a, and 6a at NS5B position 445 shows
phenylalanine as 100% conserved in those genotypes. The 1b-con-1
C445F site directed mutant fold shift in EC50 is approximately 10
compared to 1b-con-1 (Shih et al., 2011); this is signiﬁcantly lower
than the wild-type GT3a, 4a, and 6a Con chimera fold shifts to 1b-
con-1 listed in Table 2. Therefore, other residues beyond F445
within NS5B must contribute as well to the overall susceptibility to
tegobuvir because the 1b-con-1 C445F mutant EC50 is signiﬁcantly
lower than those for GT3a, 4a, and 6a. Further examination of the
role that NS5B residue C445 or F445 plays across genotypes in the
interaction with tegobuvir is warranted.
Determining direct acting antiviral activity against diverse HCV
genotypes has been challenging without the availability of full
replicons or virus systems for HCV GTs 3–6. Use of a chimeric
replicon system has been successfully employed in this study and
others to characterize DAA activity against diverse HCV genotypes
and subtypes (Binder et al., 2011; Herlihy et al., 2008). A new
standard of care has been set with the approvals of the NS3 protease
inhibitors telaprevir and boceprevir; however, these drugs are only
effective against GT1 HCV infections. Going forward, tools to assess
activity among HCV genotypes and understanding why compounds
are potent in one and not another will be critical to achieve the
ultimate goal of creating oral small molecule pan-genotype HCV
DAAs capable of achieving high SVR rates across genotypes.Materials and methods
Chimera construction
A 1b-con-1 Renilla luciferase expressing replicon was used as a
backbone for chimera construction. This replicon contained an
internal deletion in NS5B rendering it replication deﬁcient. The last
413 base pairs (encoding last 137 NS5A amino acids) of 1b-con-1
NS5A were synthesized in frame with NS5B sequences from geno-
types 2b, 3a, 4a, 5a, and 6a (Genscript Inc. Piscataway NJ). Consensus
NS5B sequences for each of these genotypes were derived by aligning
sequences deposited in the European HCV database and extracting a
consensus. These novel consensus sequences for NS5B as well as
sequences derived from individual clinical isolates (Herlihy et al.,
2008) were used to construct the NS5B chimeric replicons. A unique
XhoI site was used at the 50 end and a unique AseI site at the 30 end
to directionally clone into the 1b-hRLuc/NeoR NS5B vector via
standard molecular biology techniques.
Transient transfection and cell culture
DNA plasmids encoding full and chimeric replicons were
linearized by overnight SpeI (New England Biolabs, Ipswich, MA)
restriction digest. Digested DNA was puriﬁed by QIAquick column
puriﬁcation (Qiagen, Valencia, CA). Replicon RNA was subse-
quently transcribed using a T7 MEGAscript kit (Ambion, Carlsbad,
CA). For transfection into Huh-7 Lunet cells, cells were trypsinized
and washed two times in cold PBS. A suspension of 4106 cells in
400 mL cold PBS was mixed with 2 mg RNA in 4 mm gap width
electroporation cuvette and pulsed at 270 V and 950 mF capaci-
tance. Cells were transferred into complete cell culture medium
and seeded into appropriate plates for further analyses.
Cell lines
Huh-7-Lunet cells were obtained from ReBlikon GmbH (Mainz,
Germany). All cells were cultured in complete cell culture
K.A. Wong et al. / Virology 429 (2012) 57–6262medium [Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) with
GlutaMAX-I (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum (FBS; Hyclone, Logan, UT) 1 U/mL penicillin,
1 mg/mL streptomycin, and 0.1 mM non-essential amino acids
(Invitrogen)]. Stable 1b-con-1, 1a-H77, and 2a-JFH1 cells have
been reported previously (Lohmann et al., 1999; Robinson et al.,
2010; Shih et al., 2011). To select stable chimeric replicon cells,
transfected cells were switched to G418 (Geneticin, Invitrogen)
containing media approximately 24 h following transfection.
G418 concentration was started at 400 mg/mL but selective
pressure was lowered to 200 mg/mL for the GT3a replicon cell
line with lower replication level. Cells were continually cultured
in G418 containing media.
Compounds
Tegobuvir (GS-9190), JT-16, and the thiophene carboxylic acid
site 2 inhibitor were synthesized at Gilead Sciences, Inc. (Foster
City, CA.). HCV-796 was synthesized by Curragh Chemistries
(Cleveland, OH). A-837093 was synthesized by ChemALong
Laboratories (Lemont, IL). 20-C-methyl adenosine was purchased
from Acme Biosciences (Belmont, CA) (Fig. 1).
Antiviral EC50 determination
Stable replicon cells were trypsinized and seeded in complete
cell culture media in black 96-well plates at 4000 cells/well for
EC50 determinations. Nine point dilutions of compounds were
performed in DMSO followed by 1:100 dilutions in complete cell
culture medium for subsequent addition to cell plates. Compound
treatments were for 72 h at 37 1C in a 5% CO2 humidiﬁed incubator.
Luciferase activity was measured using the Renilla Luciferase Assay
System (Promega, Madison, WI) in a Victor X luminometer (Perkin-
Elmer, Waltham, MA). Non-linear regression and curve ﬁtting to
determine EC50 was calculated using Graphpad Prism (Graphpad
Software, Inc., La Jolla, CA).Acknowledgments
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